STOCKS TELEGRAPH

Tag: Technology

  • Tilray Inc. (TLRY) Stock Surges Following Announcement of Promising Financial Reports for Fiscal Q4 2021

    Tilray Inc. (TLRY) stock prices were up 22.47% as of the market opening on July 28th, 2021, bringing the price per share up to USD$15.69 early on in the trading day.

    Net Revenue Breakdown

    Net revenue for the fourth quarter of fiscal 2021 was reported at USD$142.2 million, up 25% from the USD$113.5 million reported for the prior year quarter. The increase was largely driven by a 36% increase in net cannabis revenue, which was reported at USD$53.7 million. This included a four wee contribution from legacy-Tilray, a 10% decline in distribution revenue, and a net beverage alcohol revenue of USD$15.9 million as a result of TLRY stock’s acquisition of SweetWater on November 25th 2020. Also contributing to the year-over-year increase was wellness revenue in the amount of USD$5.8 million from Manitoba Harvest.

    Income and Adjusted EBITDA

    Net income for the 2021 quarter came in at USD$33.6 million, a massive improvement from the net loss of USD$84.3 million reported in the prior year quarter. Adjusted EBITDA was up to USD$12.3 million during the fourth quarter of 2021, representing a massive 285% increase from the USD$3.2 million reported in the prior-year quarter. This marks the ninth consecutive quarter of positive Adjusted EBITDA.

    TLRY Stock’s Gross Profits

    Gross Profits were down to USD$22.5 million for the quarter, a 19% decrease from the USD$27.8 million reported in the prior-year quarter. Gross profits for the quarter included a one-time inventory valuation adjustment of USD$19.9 million, derived from excess inventory quantities as of the business combination with Aphria. Adjusted gross profit was reported at USD$42.4 million, a 53% increase from the USD$27.8 million reported for Q4 2020.

    Ongoing Cost Synergies

    TLRY stock anticipates facilitating significant cost synergies amounting to a total of USD$80 million within eighteen months of closing its business combination with Aphria Tilray. These cost synergies are forecasted to be focused in the key areas of cultivation and production, cannabis and product purchasing, sales, and marketing, as well as corporate expenses. So far, the company has achieved USD$35 million in synergies.

    Future Outlook for TLRY

    Armed with the success of its most recent financial reports for the last quarter of fiscal 2021, TLRY is poised to continue its trajectory of success into the new year. Current and potential investors are hopeful that management will be able to leverage the resources at its disposal to facilitate significant and sustained increases in shareholder value.

  • Grove Inc. (GRVI) Stock Surges Following Announcement of Successful Fiscal 2021 Financial Reports

    Grove Inc. (GRVI) stock prices were up 35.54% as of the market opening on July 28th 2021, bringing the price per share up to USD$6.30 early on in the trading day.

    Revenue and Net Income Reports

    July 28th 2021 saw GRVI stock, the Nevada based company that is revolutionizing the hemp industry, report preliminary and unaudited financial results for the fourth quarter of fiscal 2021, ended June 30th 2021. The company reported revenues ranging from USD$10.1 million to USD$10.4 million, representing a massive 300% increases over the numbers reported for the prior year quarter. Net income is expected to range from USD$1.5 million to USD$2 million, up from a net loss of more than USD$700,000 in the fourth quarter of fiscal 2020.

    2021 Full Year Report

    GRVI stock reported expecting full year revenues for the full fiscal year in the amount of USD$23.6 million to USD$23.9 million, a substantial 200% increase over the USD$7.4 million reported for the fiscal year 2020. Net income for the 2021 year is expected to range from USD$2 million to USD$2.5 million, up from a considerable net loss of USD$5 million for the fiscal year 2020. Full financial results for the fiscal year 2021 are expected around September 15th 2021.

    GRVI Stock Exceeding Expectations

    The company is pleased to announce having exceeded all of its internal projections for growth and profitability over the course of 2021 so far. Driven by a combination of a stellar workforce and an effectively executed business strategy, the company continued to expand the scope of its growth while sustaining profitability.

    GRVI Stock Planning to Reinvest

    The company is keen to enter the fiscal year 2022 riding the momentum generated over the fiscal year 2021. The current years financial success afford the company flexibility in investing to further consolidate and enhance internal growth. A solid balance sheet and continued positive cash flow from operations will see the company invest heavily in facilitating the growth of GRVI stock’s Products and Manufacturing. Investments are also expected to be made in an Extraction and Lab Facility to pioneer the R&D in the Hemp and Wellness industries.

    Future Outlook for GRVI

    Armed with the immense success of its preliminary and unaudited financial reports for the fiscal year 2021, GRVI stock is poised to capitalize on its momentum. The company is keen to continue its trajectory of success into the new fiscal year, hoping to drive additional growth. Investors are hopeful that management will continue to execute its strategy so as to usher in further gains in shareholder value.

  • PolarityTE Inc. (PTE) Stock on the Rise Following Announcement of Positive Topline Data from SkinTE Clinical Trial

    PolarityTE Inc. (PTE) stock prices were up 4.84% as of the market opening on July 28th, 2021, bringing the price per share up to USD$0.85 early on in the trading day.

    SkinTE Clinical Trial

    July 28th, 2021 saw the company announce the final data from its multi-center, randomized, and controlled trial, designed to evaluate the treatment of Diabetic Foot Ulcers. PTE stock’s proprietary investigational product SkinTE, in combination with standard of care, was evaluated against just standard of care alone.

    PTE Stock’s Trial’s Success

    PTE stock reported having successfully met the primary endpoint of the trial of wound closure by the twelfth week of treatment. The secondary endpoint of Percent Area Reduction (PAR) was also met, having been assesses for every even-numbered week from the fourth to the twelfth. The trial had a total enrolment of 100 participants that were split into two equal groups, with one received SOC plus SkinTE, whereas the other cohort received only SOC. The trial was conducted and evaluated across 13 different sites.

    Trial Results

    35 out of the 50 patients, representing 70% of the cohort, who received SkinTE in conjunction with SOC exhibited wound closure at 12 weeks. This is comparable to the 17 patients out of 50, representing 34%, exhibiting wound closure by week 12 with SOC only. 45 out of the 50 patients who received the SkinTE plus SOC treatment received a single application of SkinTE. Treatment with SkinTE in tandem with SOC resulted in an increase in the odds of would closure by a massive 5.37 times versus SOC alone.

    Adverse Event Reports

    The trial reported 148 Adverse events that were attributable to 49 subjects. The SkinTE plus SOC treatment cohort reported 66 AEs among 21 subjects while the SOC treatment group reported 82 Adverse Events, attributable to 28 subjects. Of this total, 26 incidents were Serious Adverse Events, with 12 occurring in the SkinTE plus standard of care across 7 subjects. 14 Serious Adverse Events were reported for the standard of care cohort, allocated across a total of 9 subjects.

    Future Outlook for PTE Stock

    Armed with the resounding success of the results of its SkinTE clinical trial, PTE Stock is poised to capitalize on the opportunities for the proliferation of the treatment. The company is keen to allocate resources towards consolidating and expanding its market footprint. Current and potential investors are hopeful that management will be able to leverage the resources at its disposal to facilitate significant and sustained increases in shareholder value.

  • electroCore Inc. (ECOR) Stock on the Rise Following Announcement of Newly Issued Patent

    electroCore Inc. (ECOR) stock prices were up 3.92% as of the market closing on July 27th, 2021, bringing the price per share up to USD$0.9665 at the end of the trading day. Subsequent premarket fluctuations saw the stock rise by 5.54%, bringing it up to USD$1.02.

    ECOR Stock’s Patent

    July 27th, 2021 announced that the United States Patent and Trademark Office (USPTO) has granted ECOR stock U.S. Patent No. 11,065,444. The patent issued to the commercial-stage bioelectronic medicine company is in regard to the use of a mobile phone for the stimulation of the trigeminal nerve to treat disorders. The new patent is owned by the company and is the most recent U.S patent to be issued in connection with the company’s development of non-invasive solution programs for pain.

    Patented Technology

    The newly issued patent includes descriptions of devices and methods that can be used by patients themselves to treat medical conditions, such as migraine headaches, with non-invasive means. ECOR stock achieves this by the electrical stimulation of nerves in the head, particularly supraorbital, supratrochlear, infraorbital, and mental nerves in the general area of patients’ foramen or notch.

    About the Treatment

    The system consists of a handheld mobile device, like a smartphone, that is applied to the surface of the head of the patient being treated. Electrical impulses are applied through the patient’s skin via one or more electrodes, serving to modulate a targeted nerve to treat the medical condition. ECOR stock’s system aims to provide patients with a self-treatment solution in the absence of a medical professional.

    Expansive Scope of Treatment

    ECOR stock is keen to continue the advancement of its non-invasive treatment solutions for its patients. The new development massively increases the scope of the reach and accessibility by which the company’s therapy may be deployed. This facilitates more patients all over the world to get the relief they need while not having to leave the comfort of their homes. This is line with the company’s vision of improving patient outcomes with its nerve stimulation therapy platform, which initially focused on the treatment of various neurological conditions.

    Future Outlook for ECOR Stock

    Armed with the security of the patenting of its proprietary technology, ECOR stock is poised to capitalize on the opportunities and tenure afforded to it over the long term. The company is keen to spearhead market penetration in an effort to usher in significant and sustained increases in shareholder growth.

  • Sintx Technologies, Inc. (SINT) Stock Undergoes Volatility Following News of First FleX SN-PEEK Shipment

    Sintx Technologies, Inc. (SINT) stock prices were up 11.04% as of the market closing on July 27th, 2021, bringing the price per share up to USD$1.71 at the end of the trading day. Subsequent premarket fluctuations saw the stock drop by 5.85%, bringing it down to USD$1.61.

    FleX SN-PEEK Shipments

    July 27th, 2021 saw SINT stock announce the first shipment of FleX SN-PEEK, its new product that is designed to be used in orthopedic implants. The company’s proprietary product commenced being shipped on July 20th, 2021, combining the singular bioactivity of silicon nitride with the properties of Zeniva PEEK, which was supplied by Solvay.

    About FleX SN-PEEK

    The composite material has been deemed to have a myriad of applications, ranging from spine surgery to joint replacements to craniomaxillofacial medical devices. On the basis of data collected by SINT stock on silicon nitride, FleX SN-PEEK is expected to facilitate faster bone healing, improved radiographic imaging, avoid metal ion release in the body, and have broad-spectrum resistance to infection as compared to PEEK in isolation.

    Advantages of FleX SN-PEEK

    The commencement of the shipping of SINT stock’s FleX SN-PEEK is a major milestone for the company. It continues to allocate resources to leverage the osteogenic and antipathogenic properties of silicon nitride for biomedical applications. The company is confident that the product differentiates itself as being superior with many unmatched benefits. Zaniva PEEK is a biomaterial that has been determined to have many advantages, signaled by its worldwide use. The advantages include favorable material modules, ease of manufacturing, established clinical record, as well as a track record of use in orthopedics.

    SINT Stock Healthcare Scope

    The combination of PEEK with silicon nitride’s osteogenic and antipathogenic properties gives rise to a superior product, FleX SN-PEEK. The catalogue of FleX SN-PEEK products provides access to new biomedical areas like craniomaxillofacial, and foot osteotomy and fusion. The proprietary technology serves to address a large unmet need stemming from surgeons constantly on the lookout for materials and procedures that result in improved outcomes with mitigated complications.

    Future Outlook for SINT

    Armed with the success of the first delivery of its proprietary technology, SINT stock is poised to capitalize on the continued development of FleX SN-PEEK. The company is keen to expand and consolidate its market footprint in order to continue its trajectory of success. Investors are hopeful that management will be able to allocate resources so as to ensure maximum gains in shareholder value.

  • Powerbridge Technologies Co., Ltd. (PBTS) Stock on the Rise Following Announcement of SCM SaaS Platform

    Powerbridge Technologies Co., Ltd. (PBTS) stock prices were up 7.94% as of the market close on July 26th, 2021, bringing the price per share up to USD$1.36 at the end of the trading day. Subsequent premarket fluctuations saw the stock rise by 11.03%, bringing it up to USD$1.51.

    PBTS Stock’s Foray into Blockchain

    July 27th, 2021 saw the company reveal that it was in the process of building a Supply Chain Management SaaS platform that will be enabled by Blockchain technology. The company is keen to spearhead its foray into Blockchain technology in an effort to optimize and integrate traditional supply chain systems. PBTS stock is a cutting-edge tech company that focuses on providing artificial intelligence, the Internet of Things, Blockchain, and financial technologies.

    About the SaaS Platform

    The company also offers SaaS solutions and operational services in various fields such as cross-border trade, smart cities, and government services. PBTS stock’s Blockchain-enabled Supply Chain Management SaaS Platform is being designed to connect suppliers, logistics service providers, distributors, retailers, and end-users. It will do so with an integrative feature network, facilitating real-time information sharing for all participants. In doing so, the company ensures the credibility of the information and facilitates the efficiency of information transmission.

    Scope of Blockchain Technology

    PBTS stock hopes for its Blockchain management platform to prove to be applicable to more practical contexts, with a deep-rooted integration with businesses. The company intends to continue developing Blockchain applications and SaaS with more trials and innovations. The application of Blockchain technology is expected to generate sustained growth of PBTS’ revenue. PBTS will also expand its application to other fields, such as supply chain finance technology.

    About PBTS Stock

    With nearly 25 years of history behind it, PBTS stock aims to provide a myriad of smart-technology-based products and solutions. These offerings include global trade-related ports and customs management platforms, cross-border and global trade solutions, smart city tech products and solutions. The company also utilizes innovative technology such as Big Data, artificial intelligence, Blockchain, and the Internet of Things.

    Future Outlook for PBTS Stock

    Armed with its foray into the burgeoning blockchain market space, PBTS is poised to capitalize on its entry into a marketspace rife with opportunities. Current and potential investors are hopeful that management will be able to leverage the resources at its disposal to facilitate significant and sustained increases in shareholder value.

  • TRxADE HEALTH, Inc. (MEDS) Stock Dips Significantly Following Disclosure of Q2 2021 Financial Reports

    TRxADE HEALTH, Inc. (MEDS) stock prices were down 4.01% as of the market closing on July 26th, 2021, bringing the price per share down to USD$5.26 at the end of the trading day. Subsequent premarket fluctuations saw the stock plummet by 19.20%, bringing it down to USD$4.25.

    Expanding Consumer Base

    MEDS stock continued to allocate resources toward the expansion of its drug procurement marketplace over the course of Q2 2021. The quarter reported having added roughly 195 new registered members, bumping the total number of registered members up to more than 12,700. The company also signed various enterprise retail partnerships to onboard new customers to its telehealth platform, partnering up with the likes of Brookshire Grocery, Winn-Dixie, and Big Y. MEDS stock’s Bonum Health product is now offered in 500 stores across all 50 states, increasing accessibility to its thousands of customers.

    MEDS Stock’s Partnerships

    MEDS stock also secured a group purchasing agreement with QualityCare Pharmacies, an independent pharmacy prescription drug buying group. QualityCare is the newest part of the company’s rapidly expanding GPO offering, aimed to drive substantial gains in wallet share amongst independent pharmacies on the TRxADE platform. MEDS stock also launched a government-oriented health passport solution with an accompanying mobile app, facilitating the expedition of post-Covid-19 reopening.

    MEDS Stock Revenue Reports

    Revenues for Q2 2021 were up to USD$1.9 million, down from the USD$6.6 million in the same quarter of the prior year. This year-over-year decrease was largely driven by non-recurring sales of personal protective equipment (PPE) in the 2020 quarter, in relation to global efforts to manage the outbreak of the Covid-19 pandemic.

    Additional Financials

    The second quarter of 2021 saw MEDS stock report gross profits in the amount of USD$0.8 million, representing 44.3% of the quarter’s revenues. This is comparable to the USD$2 million reported for the prior-year quarter, representing 30.4% of revenues. The substantial year-over-year increase in gross profit margin was largely driven by fewer lower margin PPE sales in the 2021 quarter. Operating expenses for the second quarter of 2021 came in at USD$3.4 million, up from the USD$2.5 million reported in the prior-year quarter. This increase was largely driven by an inventory investment loss of USD$1.2 million.

    Future Outlook for MEDS

    Armed with its expanding network of strategic collaborations and the success of its most recent financial reports, MEDS stock is poised to continue its trajectory of success. The company is keen to allocate resources so as to usher in further growth, with investors hoping for long-term increases in shareholder value.

  • Gaotu Techedu Inc. (GOTU) Stock Plummets Following Rising Oversight and Involvement by Chinese Government in Private Education Sector

    Gaotu Techedu Inc. (GOTU) stock prices plummeted by 24.72% some time after market trading commenced on July 26th, 2021, bringing the price per share down to USD$2.65 early on in the trading day.

    New Regulations

    China recently announced a massive set of new regulations for private education companies, primarily aimed at decreasing workloads for students. The government mandates were also designed to overhaul a marketspace that it claims has been “hijacked by capital”. The regulations ban companies such as GOTU stock that adhere to school curriculums from generating profits, raising capital, or going public. School-related tutoring can no longer be offered on weekends or during vacations. They also cannot give classes to children under the age of six, a demographic that has been increasingly pushed to start studying from an earlier age.

    GOTU Stock in Changed Landscape

    The Chinese education technology sector reached a value of USD$100 billion as companies like GOTU stock catered to the increasing number of parents wanting to give their children an early academic advantage. The regulation changes will see business models being drastically altered as companies are forced into making extensive changes in order to maintain compliance. The drastic change will see the prohibition of the overseas investments that have been the lifeblood of the sector. Companies that find themselves in violation of the new regulations are required to rectify the situation, as appropriate.

    Details of Regulations

    The private education sector attracted billions of dollars and was expected to generate USD$76 billion in revenue by 2024, of which GOTU stock hoped to be a part. The regulatory branch that aims to regulate the industry was formed in June 2021 and aims to devise and oversee the changes. The regulations were expressed in general terms, with broad applicability to common practices throughout the industry. The regulations are directed at compulsory subjects, with supplementary subjects such as art and music avoiding falling under the umbrella of the new regulations.

    Government Involvement

    The regulations were jointly announced on July 24th, 2021 by the General Office of the Communist Party of China Central Committee and the General Office of the State Council. The set of rulings aims to mitigate the excess associated with homework and after-school tutoring for students as young as six who are receiving mandatory education.

    Future Outlook for GOTU Stock

    As one of the many up and coming companies that is forced to make adjustments to adhere to the new regulations, GOTU stock is keen to capitalize on the education sector being disrupted. Current and potential investors are hopeful that management will leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • Youdao, Inc. (DAO) Stock Plummets Following Increase in Chinese Government Regulations for Educational Institutions

    Youdao, Inc. (DAO) stock prices plummeted by 29.58% shortly after market trading commenced on July 26th, 2021, bringing the price per share down to USD$8.95 early on in the trading day.

    New Guidelines for DAO Stock

    July 24th, 2021 saw the General Office of the Communist Party of China Central Committee and the General office of the State Council collaboratively issue a set of guidelines. These guidelines aim to reduce the prevalence of excessive homework and after-school tutoring for students receiving compulsory education.

    Guideline Restrictions

    The guidelines will require all institutions offering online after-school tutoring on academic subjects in compulsory education register themselves as non-profit organizations. The institutions are also required to obtain approval from the relevant regulatory authorities. The guidelines also made it compulsory to comply with various operational requirements in regard to class hours, faculty qualifications, tuition standards, advertising, and others.

    DAO Stock Explores Alternative Funding

    Furthermore, the guidelines prohibit any and all institutions from generating capital through stock exchange listings or other capital-related activities. Also prohibited are foreign investments in school curriculum-based tutoring institutions through variable interest entity arrangements, mergers, and acquisitions. Companies that are listed are prohibited from raising capital through equity offerings, with violations already having taken place expected to be corrected as appropriate.

    Working to Maintain Compliance

    While the interpretation and implementation of the guidelines are not yet completely concretized, they are expected to have material impacts on DAO stock’s K-12 course business, financial condition, and corporate structure. The company continues to investigate ways to comply with the newly introduced requirements for its K-12 course business. It will also continue to work with regulatory authorities in a bid to improve operations while staying in strict compliance with all laws and regulations. DAO also hopes to fulfill its social responsibilities, facilitating the provision of high-quality, innovative products and services to its customers. This will promote the long-term development of the education industry in China.

    Future Outlook for DAO Stock

    With an expanding umbrella of regulations and restrictions that they now have to maneuver, DAO stock is poised to capitalize on the disruption caused in the marketspace. The company is keen to regain and maintain compliance in a big to consolidate and expand its market footprint. Investors are hopeful that management will be able to effectively generate funds to fund the continue trajectory of the company’s success.

  • Lion Group Holding Ltd. (LGHL) Stock on the Rise Following Launch of Meta World NFT Online Marketplace

    Lion Group Holding Ltd. (LGHL) stock prices were up 2.48% shortly after market trading commenced on July 26th, 2021, bringing the price per share up USD$2.11 early on in the trading day.

    Launch of Meta World

    July 23rd, 2021 saw LGHL announce the launch of its subsidiary, Lion NFT Ltd.’s, non-fungible token market platform, known as Meta World. The NFT market platform will be available online before the end of July 2021. LGHL stock’s subsidiary is registered in the British Virgin Islands and conducts the bulk of its business via investments and innovations in digital assets. The parent company holds an MSB license through the U.S Treasury Department’s FinCEN., as well as an encrypted commodity operating license through the DMCC.

    LGHL Stock’s Foray into NFTs

    Leveraging these resources, Lion Group Holding Ltd. (LGHL) is poised to facilitate the provision of services such as digital asset exchange, NFT innovation, issuance, and trading on a global scale. LGHL stock’s platform is being designed to become the world’s top one-stop, cross-chain, high-expansion NFT marketplace. It will allow users to connect and trade with digital currency, as well as a digital wallet that will be linked the platform and will be accessible upon login.

    Comprehensive NFT Solution

    The new platform establishes a complete industry chain ranging from exploration and creation to pricing, buying, and selling. The platform will make use of blockchain technology to encrypt artwork such as photographs, videos, audios, and 3D pieces, while also generating relevant information that will facilitate the production of NFTs. Meta World will serve to create a foundation for an efficient digital world with the promotion of the value circulation of global resources.

    Set to Revolutionize Markets

    NFTs see illiquid digital works of art being made available to the public as valuable and investable digital collections. With the proliferation of additional NFT applications, LGHL stock’s platform will become a critical part of the digital transformation of various industries. With the global encryption economy developing rapidly, Lion Group Holding Ltd. (LGHL) is poised to capitalize on the burgeoning market with its NFT platform.

    Future Outlook for LGHL Stock

    Armed with its exciting foray into the massively expanding NFT market, LGHL stock is poised to capitalize on the added opportunities ahead of it. The company is striving to continue its trajectory of success with the efficient allocation of its resources, which investors hope will result in long-term increases in shareholder value.